The VHL (Von Hippel Lindau) syndrome is caused by a genetic mutation. This mutation occurs in a gene, also known as VHL, whose purpose is to control tumour growth. People with VHL syndrome are liable to have tumours appear in as many as ten different parts of the body, including the head or kidneys.
Constant monitoring of all these organs and early detection of tumours for people living with VHL are extremely important.
Progress in research on its cure is crucial for the lives of the people affected and strengthens our general understanding of cancer and cancer treatment.
It is a rare disease. It affects 1 individual out of 36,000.
Gene mutations provoke the growth of tumours again and again.
It is important that different areas of the body and a number of vital organs be continuously monitored to ensure early detection of tumours.